PMC:5400020 / 9827-11623 JSONTXT

{"project":"testtesttest","denotations":[{"id":"T66","span":{"begin":390,"end":402},"obj":"Body_part"},{"id":"T67","span":{"begin":458,"end":465},"obj":"Body_part"},{"id":"T68","span":{"begin":635,"end":640},"obj":"Body_part"},{"id":"T72","span":{"begin":828,"end":835},"obj":"Body_part"},{"id":"T73","span":{"begin":1007,"end":1014},"obj":"Body_part"},{"id":"T74","span":{"begin":1356,"end":1363},"obj":"Body_part"}],"attributes":[{"id":"A66","pred":"uberon_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/UBERON_0002137"},{"id":"A67","pred":"uberon_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/UBERON_0000161"},{"id":"A68","pred":"uberon_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A69","pred":"uberon_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"A70","pred":"uberon_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"A71","pred":"uberon_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/UBERON_0015230"},{"id":"A72","pred":"uberon_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/UBERON_0000161"},{"id":"A73","pred":"uberon_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/UBERON_0000161"},{"id":"A74","pred":"uberon_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/UBERON_0000161"}],"text":"Echocardiographic parameters were similar between the registries, with slightly less paravalvular leakage ≥2+ at 1 year in SAVI-2 (0.8% vs 4.1%) (Table 2, Fig. 2). The NYHA classification improved from 93.5% of patients in NYHA class III/IV at baseline to 13.0% at 1 year (Fig. 3, Supplementary Material, Table S2).\nFigure 2: Echocardiographic parameters over time (SAVI-1 and SAVI-2). (A) Aortic valve haemodynamics, measured as mean gradient and effective orifice area (EOA), and (B) percentage of patients with paravalvular leakage. Values remained stable between early follow-up at discharge/30 days and 1 year.\nFigure 3: New York Heart Association (NYHA) classification at baseline and follow-up (SAVI-1 and SAVI-2).\nTable 2: Echocardiographic assessments\nSAVI-1 SAVI-2 Total\nn = 250 n =  250 n =  500\nBaseline\n  Effective orifice area [mm2] 0.71 ± 0.21 0.75 ± 0.31 0.73 ± 0.26\n  Mean gradient [mmHg] 43.1 ± 17.4 42.2 ± 14.9 42.7 ± 16.2\nn =  219 n =  203 n =  422\n30 days Discharge/7-daysa\n  Effective orifice area 1.44 ± 0.45 1.48 ± 0.43 1.45 ± 0.44\n  Mean gradient [mmHg] 12.4 ± 5.8 12.5 ± 6.0 12.5 ± 5.9\n  Paravalvular leak\n   0: non/trace 159 (72.6) 141 (69.5) 300 (71.1)\n   1+: mild 55 (25.1) 59 (29.1) 114 (27.0)\n   2+: moderate 5 (2.3) 3 (1.5) 8 (1.9)\n   3+: moderate/severe 0 0 0\n   4+: severe 0 0 0\n1 year n = 148 n = 126 n = 274\n  Effective orifice area 1.51 ± 0.38 1.57 ± 0.40 1.54 ± 0.39\n  Mean gradient 12.9 ± 5.3 11.1 ± 4.4 12.1 ± 5.0\n  Paravalvular leak\n   0: non/trace 111 (75.0) 80 (63.5) 191 (69.7)\n   1+: mild 31 (20.9) 45 (35.7) 76 (27.7)\n   2+: moderate 5 (3.4) 1 (0.8) 6 (2.2)\n   3+: moderate/severe 1 (0.7) 0 1 (0.4)\n   4+: severe 0 0 0\nData are presented as mean ± SD or n (%). Not all measurements were available for all patients displayed,.\na whichever was earlier."}